Open-label, Multi-center, Phase I/II Study to Assess Safety, Disease Progression and Cellular Kinetics Following YTB323 Administration in Participants With Non-active Progressive Multiple Sclerosis (PMS) | MicrobiomeTrials
Open-label, Multi-center, Phase I/II Study to Assess Safety, Disease Progression and Cellular Kinetics Following YTB323 Administration in Participants With Non-active Progressive Multiple Sclerosis (PMS)
RecruitingPHASE1, PHASE2INTERVENTIONAL
Trial Details
Start: 2024-12-12Est. Completion: 2030-06-14
Enrollment target: 28 participants
Locations
Novartis Investigative Site, Darlinghurst, New South Wales, Australia
Novartis Investigative Site, Melbourne, Victoria, Australia